clinically optimal produced normal plasma levels of norepinephrine and epinephrine, but excessive concentrations of DA and its metabolites. Furthermore, the clinical and biochemical effects of L-dopa were inhibited by phenylalanine and 5-HTP, respectively, demonstrating that these amino acids have antagonistic pharmacological effects. 
As batract. We have identified a generalized deficiency of monoamine neurotransmitters in a patient with a defect in biopterin synthesis. Neurotransmitter precursors (L-3,4-dihydroxyphenylalanine [L-dopa]; 5-hydroxytryptophan and a tetrahydropterin [6- methyltetrahydropterin {6MPH4}J were investigated for their ability to normalize monoamine neurotransmitter metabolism. Before treatment, the concentrations of dopamine (DA), norepinephrine, epinephrine, and six monoamine metabolites were very low or undetectable in plasma, cerebrospinal fluid, or urine. L-Dopa and 5-HTP replacement was begun at age 7 mo. This therapy generally corrected the deficiency of monoamines and their metabolites, and improved neurological development until the age of 25 mo. Despite these benefits, the intermittent administration of L-dopa could not produce a stable improvement of acute neurological function or DA metabolism. In the 3 h after L-dopa administration, plasma DA and the motor activity and alertness of the patient rose and fell in parallel. Doses ofL-dopa that were Introduction Approximately 1-3% of patients with persistent hyperphenylalaninemia have a deficiency of tetrahydrobiopterin (BH4),' the cofactor of phenylalanine, tyrosine, and tryptophan hydroxylases (1, 2) . BH4 deficiency may result from inadequate 1 . Abbreviations used in this paper: BH4, tetrahydrobiopterin; CSF, cerebrospinal fluid; DA, dopamine; DHPG, 3,4-dihydroxyphenylethyleneglycol; DHPR, dihydropteridine reductase; DOPAC, dihydroxyphenylacetic acid; E, epinephrine; 5-HIAA, 5-hydroxyindoleacetic acid; 5-HTP, 5-hydroxytryptophan; HVA, 4-hydroxy-3-methoxyphenylacetic acid or homovanillic acid; L-dopa, L-3,4-dihydroxyphenylalanine; MHPG, 3-methoxy-4-hydroxyphenylethyleneglycol; 6MPH4, 6-methyltetrahydropterin; NE, norepinephrine; PKU, phenylketonuna; VMA, 3-methoxy-4-hydroxymandelic acid or vanillylmandelic acid.
biopterin synthesis (Fig. 1 A) (3) , or decreased regeneration by dihydropteridine reductase (DHPR) (4) . In either case, the impaired hydroxylation of tyrosine and tryptophan would be expected to reduce the formation of the catecholamines and serotonin ( Fig. 1 B) , which may account for the developmental delay and seizures of these patients. In only one patient, however, has the defect in catecholamine metabolism been studied in any detail (5, 6) . Although dopamine (DA) and epinephrine (E) levels were severely depressed, norepinephrine (NE) and its metabolites were normal. Other DHPR-deficient patients, in contrast, have had evidence of decreased NE synthesis (7) . Documentation of the monoamine deficit in additional patients has been generally limited to one or two measurements of 5-hydroxyindoleacetic acid (5-HIAA) and 4-hydroxy-3-methoxyphenylacetic acid (HVA) in cerebrospinal fluid (CSF) or urine (8) (9) (10) (11) (12) (13) . As a result, the precise nature of the catecholamine defect in BH4 deficiency remains largely unknown.
Treatment ofthe purported defects in monoamine synthesis has been attempted by the administration of L-3,4-dihydroxyphenylalanine (L-dopa) and 5-hydroxytryptophan (5-HTP) to bypass the defective hydroxylation reactions (6-9, 11, 14-16) . In some subjects, the clinical course of the disease has been favorably altered. Biochemical evaluation of this therapy, however, has been limited (6, 7, 13, 16) . In this study, we have delineated the extent of the monoamine abnormalities in a patient with a deficiency of BH4 due to a severe defect in biopterin synthesis. We measured the levels of the catecholamines and six major monoamine metabolites before L-dopa and 5-HTP administration, and then evaluated the ability of these neurotransmitter precursors to normalize monoamine metabolism during 28 mo of treatment.
In the course of this work, it became clear that serious limitations existed in the ability of L-dopa and 5-HTP to provide a physiological correction of the defects in monoamine neu- 6MPH4 has been shown to enter rodent brain 10 times more readily than BH4 (17) and to cross the blood-brain barrier of our patient (18) . In addition, it is comparable to BH4 in efficacy as a cofactor for brain tyrosine and tryptophan hydroxylases in vitro (19, 20) ; it is an excellent cofactor for rat liver phenylalanine hydroxylase (21) ; and it increases the activity ofrat phenylalanine hydroxylase in vivo (22) . During a period of withdrawal of the L-dopa, 5-HTP, and carbidopa therapy, we examined the effect of 6MPH4 on the synthesis of the monoamines and their metabolites in both the brain and the periphery of this patient. The effect of 6MPH4 on phenylalanine hydroxylation was also evaluated.
Methods
Subject. The (27) , and plasma L-dopa by high-pressure liquid chromatography using electrochemical detection (28) . Specimens of lumbar CSF for 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), DHPG, HVA, 3-methoxyl-4-hydroxymandelic acid (VMA), and 5-HIAA quantitation were the initial 2-3 ml of fluid to be collected, and were dripped into tubes containing ascorbic acid (1 mg/ml), and then frozen at -20'C until assay by a gas chromatography-mass spectrometric method (29) (30) (31) (32) . Specimens ofurine for MHPG, tryptamine, DHPG, HVA, VMA, and 5-HIAA were collected into brown bottles on ice, and then frozen at -20'C until assay by gas chromatography-mass spectrometry (29) (30) (31) (32) , or for 5-HIAA by fluorometric assay (33) . Urine specimens for dopamine (DA) quantitation were collected in acid-containing bottles and frozen at -20'C until analysis. DA was measured in random urine samples by a high-pressure liquid chromatographic method using electrochemical detection (34) .
Results

Diagnosis of biopterin synthesis defect
The clinical presentation suggested that the patient had a deficiency of BH4. This was confirmed, and shown to be due to a defect in biopterin synthesis, by the following studies.
Intravenous BH4 infusions: effect on plasma phenylalanine and tyrosine. In RH4 deficiency, the administration of BH4 reduces the plasma phenylalanine concentration to normal levels (23). BH4 (2.3 mg/kg) infused intravenously into our patient at 8 and 24 mo of age normalized the plasma phenylalanine, an effect that lasted up to 19 h (Fig. 2 A) . Plasma tyrosine increased threefold in the hours after each BH4 injection (Fig. 2 A) .
Neopterin and biopterin concentrations in extracellularfluids.
Neopterin accumulation is characteristic of patients with defective biopterin synthesis (24). The urine neopterin/biopterin ratio of our patient was 655, 300-fold greater than normal (35) . The serum neopterin/biopterin ratio of 40 was also increased (normal for age: 2.4+0.8, mean±SD [35] ). Similarly, the CSF neopterin (69.3 ng/ml) was elevated, while the concentration of biopterin (0.81 ng/ml) was greatly decreased (adult controls: 12.2±8.4 ng/ml and 18.6±12.7 ng/ml, respectively, n = 5). In addition to increasing the serum biopterin ( Fig. 2 B) , the intravenous infusion of BH4 decreased the serum neopterin by 80%. No increase was detected in the biopterin concentration of CSF sampled 3 h after the intravenous injection of 2.5 mg/ kg BH4 (data not shown).
In one patient with a biopterin synthesis defect, the expected increase in serum biopterin did not occur following phenylalanine loading (3) . Similarly, no increase occurred in our patient. The serum biopterin was <1.0 ng/ml before the test (100 mg/ kg phenylalanine) and remained at this level from 1 to 4 h after phenylalanine administration. Using ring-tritiated phenylalanine (3 gCi/kg) (3, 36) , in vivo phenylalanine hydroxylation was also measured during this phenylalanine load, and found to be only (Fig. 4) . After L-dopa and carbidopa alone, plasma dopa and DA rose acutely and were maximal at 30 min (study 1, Fig. 4 ). termn from study 2 of Fig. 2 A. The rise in the serum biopterin con-7.3 mg). In contrast to these abrupt changes, NE and E levels centration is associated with a fall in serum neopterin that lasted remaIn st to these (dat ngeshown).
-24 h. The plasma phenylalanine (Fig. 2 A) (Table II) . NE was only 20% of adult controls, whose mean value was similar to that obtained in a 6-mo-old patient with classical PKU (Table II) . The L-dopa, 5-HTP, and carbidopa therapy normalized the DA and E concentrations, and increased NE two to threefold. The monoamine metabolites MHPG, DHPG, HVA, and 5-HIAA could not be detected in CSF before commencing the L-dopa, 5-HTP, and carbidopa treatment (Table II) . After 11 d of therapy, MHPG, HVA, and 5-HIAA each increased to the normal range (Table II) . When the doses of the drugs were later reduced according to clinical criteria (see below), HVA was only one-tenth that of controls at 35 mo, while 5-HIAA was onehalf of controls (Table II) .
NEUROTRANSMITTER METABOLITES IN URINE. The urinary excretion of MHPG, HVA, and VMA was very low or undetectable before treatment (Table III) , while all three metabolites reached or exceeded the control range during L-dopa, 5-HTP, and carbidopa administration. The relatively high excretion of HVA observed before therapy was also apparent during therapy (Table III) . HVA excretion increased to levels up to 10-fold above the mean ofcontrols, whereas MHPG and VMA excretion rose to levels ranging from only 25 to 100% of the mean of controls. The excretion of 5-HIAA was <5% of PKU controls before treatment, but increased to levels up to sixfold above the range of the controls during therapy. On the other hand, tryptamine excretion (0.71, 0. Blunting ofthe clinical response to L-dopa by phenylalanine loading. We repeatedly observed that phenylalanine loading tests dramatically suppressed the beneficial effect of L-dopa on neurological function. In six studies over a 3-yr period, a normal diet raised the plasma phenylalanine to 1-3 mM. Despite continued L-dopa-5-HTP-carbidopa therapy on each occasion, the patient was incapable of many ofthe motor functions she readily performed only 24 h previously, and which she recovered within hours of reducing the phenylalanine.
Effects of 6MPH4 administration
The studies with 6MPH4 assessed whether this reduced pterin could: (a) increase the activity of phenylalanine hydroxylase; (b) be absorbed adequately by the gut to allow oral administration; (c) cross the blood-brain barrier in the reduced state; and (d) increase the activity of peripheral and/or central tyrosine and tryptophan hydroxylases in this patient.
6MPH4: effect on phenylalanine concentration in plasma.
With the patient on a normal phenylalanine diet (130 mg/kg per d), intravenous 6MPH4 (5 mg/kg) reduced the plasma phenylalanine by 30% in 3 h (Fig. 5 A) . A higher dose (10 mg/kg) was more effective, decreasing the phenylalanine from 1.0 mM to 0.2-0.3 mM for 18 h (Fig. 5 A) . Plasma tyrosine rose as the phenylalanine fell (Fig. 5 A) , as it had done following the injection of BH4.
6MPH4, given by gastrostomy tube in increasing doses (2-8 mg/kg per d), began to reduce the phenylalanine at a dose of 4 mg/kg per d (Fig. 5 B) . At 8 mg/kg per d, the phenylalanine was 0.6 mM, one-half its pretreatment level. In addition, after 8 After 12 d of 6MPH4, the CSF concentration ofthis reduced pterin was 60.5 ng/ml when the serum level was 88.5 ng/ml. The entry of 6MPH4 into the CSF of this patient has been discussed in more detail elsewhere (18) . 6MPH4 reduced the neopterin concentration in CSF from 66.5 to 47.9 ng/ml and in serum from 130 ng/ml to 70.7 ng/ml.
Withdrawal of L-dopa, 5-HTP, and carbidopa reduced the concentrations of the monoamines or their metabolites in plasma, CSF, and urine to subnormal levels (Tables I-III, bottom  rows) . 6MPH4 increased the urinary excretion of HVA and 5-HIAA (Table III) adults, anesthetized for clipping of a cerebral aneurysm. if CSF taken before and after intravenous BH4 at 24 mo age. § § L-Dopa, etc. = Ldopa, carbidopa, and 5-HTP. 1111 The first row of catecholamine results were obtained in the Ist ml of CSF. The second row is from the 4th ml.
major metabolites, as well as 5-HIAA (the principal catabolite of serotonin) (Fig. 1 B) in a patient with a severe defect in biopterin synthesis. Treatment of this monoamine deficiency with L-dopa and 5-HTP resulted, acutely, in a dramatic restoration ofalertness, muscle tone, and motor activity, and, during the first 18 mo oftherapy, in a rapid acceleration ofdevelopment. The provision ofL-dopa and 5-HTP also corrected the deficiency of the monoamines and their metabolites in plasma, urine, and CSF. That the effect of L-dopa and 5-HTP on monoamine metabolism is far from physiological, however, is shown by the findings of abnormally high levels of plasma DA and its metabolites, the close dependence of plasma DA on the time after the administration of L-dopa, the brevity of the period during which the clinical response to L-dopa is optimal, the presence of normal levels of a metabolite in one body fluid concomitant with its excess in another (e.g., 5-HIAA in CSF vs. urine), and the inhibition by 5-HTP (and probably also phenylalanine) of the conversion of L-dopa to DA. Since a more physiological restoration of the defective hydroxylation reactions might be expected to result from the administration ofa tetrahydropterin, we evaluated the effect of 6MPH4 on phenylalanine and monoamine metabolism. Despite the ability of6MPH4 to be absorbed by the gut, control the hyperphenylalaninemia, and cross the blood-brain barrier, this pterin demonstrated no neurological effect and no ability to increase monoamine synthesis in the brain. Consequently, for BH4-deficient patients who do not respond to tetrahydropterin therapy with an increase in monoamine synthesis by the brain, L-dopa, 5-HTP, and carbidopa still represent the best available treatment. Considerable research is required in the use of these drugs in BH4-deficient patients, however, before the most beneficial results can be expected. The studies of pterin metabolism in our patient corroborate and extend the findings reported for the first case of a biopterin synthesis defect (3) . The rapid reduction in plasma phenylalanine by BH4 confirms the diagnostic value of this test (16, 23, 40) in patients with defects in biopterin synthesis. The increase in plasma tyrosine, which occurred following BH4 or 6MPH4 administration, has not been previously reported, but undoubtedly reflects increased tyrosine formation from phenylalanine.
The BH4-and 6MPH4-induced depression of serum neop- In the studies using 6MPH4, we have shown that this tetrahydropterin can be administered orally to control the hyperphenylalaninemia of BH4 deficiency. The more crucial question, however, is why 6MPH4 did not stimulate monoamine synthesis in the brain ofour patient. The increases in the urinary excretion of DA, HVA, and 5-HIAA produced by 6MPH4 presumably reflect the stimulation of tyrosine and tryptophan hydroxylase in peripheral tissue(s). Since identical doses of6MPH4 IL.1.0 increased the activity of tyrosine and tryptophan hydroxylase in the brain of a patient with a less severe defect in biopterin synthesis (42) , the unresponsiveness of our patient is not representative, nor is it easily explained. One possibility is that the absence of monoaminergic activity during brain development has led to the underdevelopment ofmonoaminergic target areas (43, 44) and to greatly decreased numbers of monoaminergic neurons (45) . Our patient may therefore have insufficient numbers of monoaminergic neurons to respond to 6MPH4, but the exposure of this reduced number of neurons to an excess of the precursor L-dopa, as in Parkinson's disease, is able to normalize catecholamine concentrations in CSF.
In contrast to the DHPR-deficient subject of Koslow and Butler (5, 6) , who had normal NE metabolism, the biopterin defect in our patient severely depressed the synthesis of NE as well as DA and E. Since other DHPR-deficient patients have had evidence of impaired NE synthesis (7), the patient of Koslow and Butler may be atypical. Our results, in combination with reports of decreased 5-HIAA, HVA, or VMA in other BH4-deficient subjects (8) (9) (10) (11) (12) (13) , indicate that the defect in monoamine synthesis is very similar in DHPR-deficient and biopterin-deficient patients. Finally, since DA is an established inhibitor of prolactin secretion (46) , the hyperprolactinemia of our patient also indicates that a hypothalamic DA deficiency was present before treatment. A patient with a less severe defect in biopterin synthesis, in contrast, had normal prolactin levels (42) .
The striking fall in plasma NE and E levels with age in our control hyperphenylalaninemic population highlights the importance of using age-matched controls in the diagnosis and treatment of monoamine deficiency. The increase with age in the urinary excretion of HVA and VMA, which we observed, has also been reported by others (47) .
Inspection of the biochemical effects of L-dopa and 5-HTP leads to two major conclusions. First, normalization of the levels of a monoamine or a metabolite in one extracellular fluid is not necessarily associated with normalization of its concentrations throughout the body. The dose of L-dopa that corrected the CSF HVA at 7.3 mo of age, for example, produced supranormal urinary HVA excretion. Similar observations have been made during the treatment ofparkinsonism (48, 49) , and indicate that HVA formation may take place via pathways not requiring sequential DA and DOPAC formation (50) . Second, both strikingly elevated and depressed levels of specific monoamines or metabolites can result from the treatment. The elevation of plasma DA, in the presence of normal NE and E, implies that the conversion of DA to NE becomes rate-limiting during Ldopa replacement in this disease. The pronounced depression of tryptamine excretion, on the other hand, is best explained by the competitive inhibition of aromatic amino acid decarboxylase by 5-HTP and L-dopa (51).
Some of the biochemical abnormalities we observed with L-dopa and 5-HTP replacement, for example the elevation of plasma DOPAC, may be ofno clinical importance. Others, such as the reduced conversion of dopa to DA by 5-HTP, are of therapeutic significance. Consequently, the dose of 5-HTP cannot be changed without affecting the pharmacology of L-dopa, and vice-versa. This 5-HTP-L-dopa interaction is likely to be at the level of transport (52) or aromatic amino acid decarboxylase, and reflects the structural similarity of these amino acids. Similarly, the effect of phenylalanine on the clinical response to L-dopa also probably reflects transport inhibition (52), or an inhibition by phenylalanine of monoamine synthesis from L-dopa, as has been demonstrated in PKU (7, 53) . Treatment of the hyperphenylalaninemia with low doses (2 mg/kg per d) of tetrahydropterins would avoid the fluctuations in plasma phenylalanine that accompany dietary therapy, and perhaps optimize the response to L-dopa replacement.
Our preliminary data (18, 42) and those of Niederwieser et al. (14) show that therapy with a tetrahydropterin may be effective in treating the defect in monoamine synthesis in some patients with BH4-deficiency. These findings imply that in all newly diagnosed hyperphenylalaninemic patients who have a defect in brain monoamine synthesis, a trial of high dose BH4 should be given. However, clinical trials using high doses of BH4 or 6MPH4 must be monitored with great care, since virtually nothing is known about the toxicity of the tetrahydropterins. The results presented in this paper and others (14, 16) indicate that certain patients will not be neurologically responsive to high dose pterin treatment; as we have shown, such patients may still respond, at least partially, to L-dopa and 5-HTP (8, 9, 13, 16) . The limited response of our patient may be related to the premature removal of maternally derived BH4 due to the 35-wk-gestation, the late age at which treatment was begun (7 mo), and/or to the severity ofher defect. The most important question, whether infants unresponsive to tetrahydropterins can achieve normal development if treated early with L-dopa and 5-HTP, remains to be answered.
